Does Insurance Cover GLP-1s? Wegovy, Zepbound, Ozempic

Short answer: sometimes — and what decides it is the indication on your prescription, not the molecule in the pen. Semaglutide prescribed as Ozempic for type 2 diabetes is covered by most commercial plans and by Medicare Part D. The exact same molecule prescribed as Wegovy for weight management is excluded outright by a large share of employer plans. Same story for tirzepatide: Mounjaro (diabetes) is usually on formulary; Zepbound (obesity, or obstructive sleep apnea with obesity) often is not. We cannot tell you what your specific plan does. We can tell you exactly what to ask.

The distinction that decides everything

Insurers do not cover "semaglutide." They cover a drug for a use, and they build the benefit around that use. Weight-management drugs sit in a category that plan sponsors — usually your employer, not the insurance company — can choose to carve out entirely. When a plan carves out weight-loss drugs, no prior authorization, no appeal and no doctor's letter will conjure a benefit that does not exist in the contract. That is the single most useful thing to establish first, because it changes what you do next.

How common is the carve-out? In KFF's 2025 Employer Health Benefits Survey — the most recent national figures as of July 2026 — among firms offering health benefits, 43% of firms with 5,000 or more workers covered GLP-1s when used primarily for weight loss (up from 28% the year before), but only 16% of firms with 200–999 workers did. At a very large employer it is close to a coin flip. At a mid-sized one it is the exception.

So before anything else, find out which of these three situations you are in:

1. The drug is excluded from the benefit. Weight-management drugs are carved out. Nothing clinical will change this; only a plan change (or a different, covered indication) will.
2. The drug is covered but restricted. It is on the formulary behind prior authorization and possibly step therapy. This is winnable with documentation.
3. The drug is covered with ordinary cost-sharing. Rare for weight management in 2026, common for diabetes.

Drug → FDA indication → typical coverage picture

Indications below are from the current FDA labels (checked July 2026 against FDA approval records and the manufacturers' prescribing information). The coverage column describes the typical pattern in the US market, not your plan.

Read that table once more and notice what it implies: two people can be prescribed the identical molecule, at the identical dose, and one pays a modest copay while the other pays several hundred dollars a month — because of which brand and which diagnosis code is on the claim. That is not a loophole to exploit. It is a fact about how benefits are written, and it is why the honest first question is diagnostic, not tactical. (More on how the drugs differ clinically: Wegovy vs Ozempic and Zepbound vs Wegovy.)

Medicare: the rule, and the temporary bridge

By statute, Medicare Part D has never been allowed to cover drugs used for weight loss alone. That has not changed. What has changed is around the edges:

• Part D can cover a GLP-1 for a non-weight indication. Type 2 diabetes, obstructive sleep apnea and noncirrhotic MASH are covered indications. If you have documented OSA and obesity, Zepbound can be a Part D drug for you. If you have type 2 diabetes, Ozempic or Mounjaro can be.
• The Medicare GLP-1 Bridge started July 1, 2026. Under this temporary CMS demonstration, eligible Part D beneficiaries can get weight-management GLP-1s — all formulations of Wegovy and Foundayo, plus the Zepbound KwikPen — for a flat $50 a month that does not rise as the dose goes up. CMS has said the program runs through December 31, 2027. Your prescriber must attest that you meet the criteria, which as published by CMS are: a BMI of 35 or more; or a BMI of 30 or more with heart failure, uncontrolled hypertension or chronic kidney disease; or a BMI of 27 or more with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Two things people get wrong. The Bridge sits outside the Part D benefit, so the $50 does not count toward your deductible or toward the Part D out-of-pocket cap ($2,100 in 2026). And if your GLP-1 is already covered by Part D under another indication (diabetes, OSA, MASH), you use Part D, not the Bridge.
• The Part D piece of the broader BALANCE model was shelved. CMS delayed it indefinitely in spring 2026 — it said it wanted more utilization data, after weak sign-up from Part D plan sponsors. Do not plan around it. The Medicaid piece of BALANCE is still going ahead, with states able to join.

Medicaid varies by state, a lot. Covering GLP-1s for obesity is optional for states, and in 2026 roughly 13 state Medicaid programs did so — down from 16 the year before, after California, New Hampshire, Pennsylvania and South Carolina dropped the benefit on cost grounds. Coverage for diabetes is a separate question and is broadly available. If you are on Medicaid, the real answer lives in your state's preferred drug list, and it can change mid-year.

Prior authorization and step therapy, in plain English

Prior authorization (PA) means the plan will not pay until your prescriber submits proof that you meet the plan's written criteria. It is a paperwork gate, not a medical judgment about you. For weight-management GLP-1s, the criteria almost always ask for three things:

• A documented BMI — typically 30 or higher, or 27 or higher with a weight-related condition (hypertension, dyslipidemia, type 2 diabetes, sleep apnea). "Documented" means measured and recorded in the chart, not reported over the phone.
• A comorbidity, coded. If the BMI is in the 27–29.9 range, the comorbidity is what makes you eligible. It has to appear as a diagnosis code, not as a sentence in a note.
• Prior attempts. Many plans want evidence of a documented lifestyle or weight-management program, often of a set length (3–6 months is common), before they will authorize a drug. In KFF's 2025 survey, about a third of firms that covered these drugs for weight loss required enrollees to see a dietitian, case manager or therapist, or take part in a lifestyle program, as a condition of coverage.

Step therapy ("fail first") means the plan requires you to try a cheaper option and have it not work before it will pay for the expensive one. In this class that can mean trying a different weight-management medicine first, or in diabetes, metformin before a GLP-1.

Denials here are frequently procedural rather than clinical — a weight that was never recorded, a comorbidity written in prose instead of coded, a lifestyle program that was never named. That is worth knowing, because those denials are the fixable kind. Ask the plan for the written criteria and for the specific denial reason in writing, then ask your prescriber's office whether the chart already contains what the criteria require. What we will not do is help you word anything so that it says something untrue. Misrepresenting a diagnosis or a history to an insurer is insurance fraud, it puts your prescriber's license at risk, and we will not help with it.

The exact questions to ask your insurer

Call the member services number on the back of your card, ask for the pharmacy benefit, and get a reference number for the call. Then ask, in these words:

1. "Does my plan exclude weight-loss or anti-obesity medications as a category?" (If yes, stop here and go to question 6.)
2. "Is [drug name] on my formulary, and at what tier?"
3. "Does it require prior authorization or step therapy? Can you email or mail me the written PA criteria?"
4. "If it is covered, what is my cost — copay or coinsurance — and does my deductible apply first?"
5. "Is there a quantity limit, and is it restricted to a specific pharmacy or specialty pharmacy?"
6. "Is there any indication under which this drug would be covered on my plan?" (This is how you learn whether the cardiovascular, OSA or diabetes route exists on your plan — information you then take to your clinician, who decides what is clinically true for you.)

If the answer is an exclusion, the next call is not to the insurer. It is to your employer's HR or benefits team, because the exclusion is usually their purchasing decision and it is revisited at annual renewal. Our cost and coverage estimator can help you map the scenarios before you call.

If your plan says no: the honest options

Manufacturer self-pay channels now exist, and they are cheaper than the old list prices — but they are still real money, indefinitely, and the terms move. The prices below were checked on the manufacturers' own pages in July 2026. They are not promises: both companies can change them, and several are time-limited introductory offers with published end dates.

• Zepbound, LillyDirect self-pay (checked July 2026): $299/month for 2.5 mg, $399/month for 5 mg, and $449/month for every dose from 7.5 mg to 15 mg — paid in cash, not billed to insurance. The $449 tier comes with a condition worth reading twice: it holds only if you buy your refill within 45 days of your previous delivery. Miss that window and the standard self-pay price applies, which Lilly currently lists as $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg and $1,049 for 15 mg.
• Wegovy, NovoCare Pharmacy self-pay (checked July 2026): new patients are offered $199/month for their first two fills of the injection, an offer Novo Nordisk states runs through December 31, 2026; the listed price after that is $349/month for the 0.25–2.4 mg doses and $399/month for the 7.2 mg high dose. Wegovy tablets are listed at $149/month, with the 4 mg price stated as an introductory rate through August 31, 2026 and $199/month afterwards.
• Wegovy savings card: if you have commercial insurance that does cover Wegovy, Novo Nordisk's savings offer advertises "as little as $25 a month," subject to a stated cap on the amount it will pay per fill. As with every manufacturer copay card, people on Medicare, Medicaid or other federal programs are not eligible.

Two more things people ask about. Compounded versions are not FDA-approved products. They are not reviewed by the FDA for safety, effectiveness or manufacturing quality, and the rules tightened once the semaglutide and tirzepatide shortages were declared resolved. The FDA has specifically warned about dosing errors with compounded GLP-1s dispensed as a vial plus a syringe: patients — and in some reports, health professionals — miscalculated the dose and drew up five to twenty times the intended amount, and some of those overdoses ended in the emergency room or in hospital. Whether to use a compounded product is a decision for you and a clinician who knows your history; we are not going to tell you either way. But you should know that "compounded semaglutide" is not the same regulatory thing as Wegovy. And telehealth can be a legitimate route to a prescription; judge a provider by whether a licensed clinician actually evaluates you, whether they will send the prescription to any pharmacy you choose, whether the full price is disclosed before you pay, and whether you can reach a human being when side effects start. We do not recommend specific telehealth companies or pharmacies. See how to evaluate online GLP-1 care.

Disclosure: VidaBeacon may earn a commission from some links in our care-finder and product pages, including links to telehealth services. Commissions never affect what we cover, what we say about coverage, or what appears in our comparisons. We are not paid by Eli Lilly or Novo Nordisk; the prices above are reported from their public pages, not sponsored.

Talk to your prescriber — and when to do it sooner

Bring the plan's written PA criteria to your appointment and ask your clinician a direct question: "Based on my actual history, is there an indication on this list that applies to me, and is it documented?" That is a clinical question with a clinical answer, and it belongs to them, not to us.

A boundary that matters more than money: your prescriber sets your dose. The FDA labels publish titration schedules, and that is public fact you are entitled to read (summarized here) — but a published schedule is not an instruction to you, and nothing on this page is either. Do not self-adjust. Do not stretch a pen or a vial to make it last, do not split or re-measure doses, do not double up or take an extra dose to catch up after a missed one, and do not restart at your old dose after a gap in supply without asking first. Cost pressure is exactly the situation that tempts people into all of these, and each one can hurt you. If you miss a dose or run out, ask your prescriber or pharmacist what to do — the right answer depends on the drug, the dose and how long the gap was.

Contact your prescriber promptly if you cannot afford your next fill (there may be a covered alternative, another indication, or a program you do not know about), if you have had to stop suddenly, or if you develop severe or persistent abdominal pain, repeated vomiting or signs of dehydration, symptoms of gallbladder trouble, new vision changes, or symptoms of low blood sugar. Seek urgent care for severe, unrelenting abdominal pain that spreads to your back, or for signs of an allergic reaction such as swelling of the face or throat or trouble breathing.

Related reading: how GLP-1 drugs work, tirzepatide: Mounjaro vs Zepbound, Ozempic and Wegovy side effects, and our weight and metabolism hub.